Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

nt was achieved by patient controlled analgesia (PCA), whereby the patient was allowed to self administer a dose of M6G or morphine as required to control their pain. The study was randomised and double blind so that neither patient nor carer was aware of which treatment was being administered. The main purpose of the study was to demonstrate statistically that:

- Treatment with either M6G or morphine, particularly during PCA, results in similar levels of pain management; and

- Effective analgesic treatment during PCA results in lower levels of nausea and vomiting in patients receiving M6G compared to those receiving morphine.

In addition, other important side effect, efficacy and safety features were determined throughout the study.

Summary of Phase III trial (M6G022) results

1. M6G matches morphine for analgesic effect

Importantly for a novel pain product, the trial results unequivocally show that M6G is as good as morphine in terms of analgesia achieved in patients up to 48 hours post-operatively. Successful achievement of this first primary endpoint supports data from previous clinical trials of M6G and is an essential component in the product profile of M6G.

2. M6G shows significant reduction in post-operative nausea and vomiting compared to morphine

The trial results confirm the excellent potential of M6G as an analgesic with a clinically significant improved side effect profile compared to morphine. The study results show that patients receiving M6G experienced a 28% reduction in the severity of post-operative nausea and vomiting (PONV) in the key 6 - 24 hours after treatment (statistically significant, p=0.018).

In addition, the incidence of dry retching/vomiting in the M6G arm compared to the morphine arm in the 24 hour period after treatment was reduced by 32% ( statistically significant, p= 0.044). The incidence and severity of post-operative nausea in the M6G arm was 27% less than that observ
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:12/15/2009)... 15 Sonic Innovations, Inc. (Sonic), a ... solutions, donated $10,000 to its local Feeding America ... 2009. ,, Sonic Innovations President Paul Wennerholm presented ... member, the Utah Food Bank, at the nonprofit ... participated in an office food drive and volunteered ...
(Date:12/15/2009)... -- Champions Biotechnology, Inc . (OTC Bulletin ... of advanced preclinical platforms and tumor specific data ... announced its financial results for the second fiscal ... of Company,s financial results are available in the ... Total revenues for the second quarter of 2010 ...
(Date:12/15/2009)... Dec. 15 The U.S. Food and Drug ... today voted 12 yes, 4 no, and 1 abstention ... observed risks to support the use of CRESTOR® (rosuvastatin ... Men greater than or equal to 50 years, women ... Fasting LDL < 130 mg/dL; hsCRP greater than or ...
Breaking Medicine Technology:Sonic Innovations, Inc. Donates $10,000 to Feeding America 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography 28PET 29 Myocardial Perfusion Imaging 28MPI 29 Tracer 48848 1FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography 28PET 29 Myocardial Perfusion Imaging 28MPI 29 Tracer 48848 2Nanopoint Applies CE Mark to Its cellTRAY 28R 29 Imaging and Microfluidics Systems 12612 1Nanopoint Applies CE Mark to Its cellTRAY 28R 29 Imaging and Microfluidics Systems 12612 2iCardiac Selected for Multiple Cardiac Safety Studies 12609 1iCardiac Selected for Multiple Cardiac Safety Studies 12609 2
... HIV Infection ... of Immune System Cells, ... ) today announced that it has initiated two large,Phase III ... a single 30 mg tablet in combination,with an optimized background ...
... 13 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today ... its clinical development and discovery,programs at four upcoming investor conferences: ... Presentation: Monday, September 17, 2007 at 10:00 a.m. ... at the St. Regis Hotel in San Francisco ...
Other Medicine Technology:Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients 2Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients 3Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients 4Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 3
(Date:12/15/2009)... Palo Alto Networks(TM), the network security ... its PA-4000 Series next-generation firewalls for accurate threat ... visibility and control over applications such as peer-to-peer ... national university with eight facilities on five campuses. ... a number of academic schools and institutions throughout ...
(Date:12/15/2009)... 15 Vitech Systems Group, a leading ... (CRM) software, announced today that it has completed ... the Screen Actors Guild-Producers Pension & Health Plans ... service capabilities to SAG-PH call center personnel in ... installed using Vitech,s V3 Benefits Administration System which ...
(Date:12/15/2009)... lower strength than needed for protection, CDC says, , , ... doses of H1N1 swine flu vaccine have been recalled ... some potency, federal health officials said Tuesday. , According ... the company,s routine testing of the vaccine for children ... four batches had lower than required potency levels. "This ...
(Date:12/15/2009)... Dec. 15 Knowledge ... the pharmaceutical and bio-tech research market with ... Over the past 11 years CMR has ... Consulting Network (PCN®), which now includes 70,000 ... both primary care and hard-to-reach specialties. ...
(Date:12/15/2009)... following are the remarks by Lanny A. ... at the Medicare Fraud Strike Force press conference: ... for the enormous effort everyone at HHS is ... our Departments have and will continue to accomplish ... progress in fighting Medicare fraud in South Florida, ...
Breaking Medicine News(10 mins):Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3
... New Poll Finds Californians Overwhelmingly Oppose Mandatory Health,Insurance, ... Calif., Jan. 15 The following,is being issued ... What:, At a press conference, a Massachusetts ... will discuss his plight and why,Californians should not ...
... Nancy Pelosi and,senior House Democrats hosted a health ... in public policy, academia, business, medicine,with key legislators ... our health care,system., "As Americans, concerns grow ... and loss of coverage, the New Direction Congress ...
... Physicians Service,Insurance Corporation (WPS) filed a lawsuit in Milwaukee ... WPS,s contractual,relationship with HealthEOS by MultiPlan, an independent primary ... terms of its contract with,WPS. This action was taken ... face with Aurora and HealthEOS to resolve these issues ...
... to data,from the 2000 US Census, Pennsylvania,s ... United States behind Florida. Widener University, in,conjunction ... "The Widener Elder Pennsylvanian Survey," aimed at ... talked to baby boomers and,centenarians about their ...
... depression, anxiety more likely to have children with airway ... born to mothers who have persistent depression or anxiety ... suggests. , Canadian researchers report a 25 percent increase ... exposed to maternal distress from birth to age 7. ...
... − Researchers at Lombardi Comprehensive Cancer Center at Georgetown ... as cyclin D1 may be the Achilles heel for ... which is the most common type of breast cancer. ... the journal Oncogene, investigators say the findings support testing ...
Other Medicine News:Health News:Massachusetts Teacher Facing Unaffordable Mandatory Health Insurance Speaks Out Against CA Mandate Proposal 2Health News:Pelosi, Democrats Host Health Care Forum This Morning 2Health News:Pelosi, Democrats Host Health Care Forum This Morning 3Health News:Pelosi, Democrats Host Health Care Forum This Morning 4Health News:Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 2Health News:The Widener University 'Elder Pennsylvanian Survey' Finds Pennsylvania's Baby Boomers Anticipate Working Longer, Retiring Later to Help Offset Looming Health Care Costs 2Health News:The Widener University 'Elder Pennsylvanian Survey' Finds Pennsylvania's Baby Boomers Anticipate Working Longer, Retiring Later to Help Offset Looming Health Care Costs 3Health News:The Widener University 'Elder Pennsylvanian Survey' Finds Pennsylvania's Baby Boomers Anticipate Working Longer, Retiring Later to Help Offset Looming Health Care Costs 4Health News:Maternal Distress Raises Risk of Childhood Asthma 2Health News:Maternal Distress Raises Risk of Childhood Asthma 3Health News:Findings point to molecular 'Achilles heel' for half of breast cancer tumors 2Health News:Findings point to molecular 'Achilles heel' for half of breast cancer tumors 3
... of Protein C Activity by ... free of Protein C; highly ... contortrix venom for specific activation ... an activator selected specially for ...
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Medicine Products: